Healthcare Financial News

ChrysCapital which acquired an 80% stake in GeBBS in 2018 for $140 million at a valuation of $175 million. ChrysCapital has hired US investment bank and capital markets firm Jefferies to run the sale process and feelers have been sent to global buyout funds, the people said. Founders of GeBBS who hold the residual stake in the company will also exit in this round, said the people cited above. GeBBS posted revenue of about $200 million in FY24, the people said. GeBBS and ChrysCapital didn’t respond to queries.

Lancet, a leading medical journal, claimed that the Indian government's data on healthcare is inaccurate and opaque, the latter's officials said that the country has a robust system which documents births and deaths under a legislation. «It (data under Registration of Births and Deaths Act, 1969) provides a unified process of continuous, permanent, compulsory, independent and universal recording of births and deaths,” TOI quoted government officials as saying. Further, the officials said that over 90 per cent of births and deaths are registered online on the state or national portals.

INDIA bloc has failed to gain much traction as its important allies JD(U) and RLD have walked out. He asserted that India needs greater empowerment for the underprivileged through better education, healthcare, and gender equity. “A cast census might be an exercise to consider.

India has lost much of its power due to disunity, Nobel laureate Amartya Sen said the Congress has many organisational problems that need remedying. In an interview with PTI, Sen said that a caste census might be an exercise to consider, but India needs greater empowerment for the underprivileged through better education, healthcare, and gender equity. The noted economist said he is «enormously proud» to be a citizen of a democratic country like India, but there is a need to «work harder to enhance the nation's democratic nature». Sen said the opposition bloc INDIA failed to gain much traction, with its important allies such as JD(U) and RLD walking out.

A two-decade bet on a biotechnology company turned into a roughly $8 billion windfall for investors in a New York hedge fund earlier this year. Baker Bros. Advisors, a hedge-fund firm run by brothers Felix and Julian Baker, had in 2003 invested in Seagen, a developer of next-generation cancer treatments.

Congress party and the Bharatiya Janata Party (BJP) have released their respective manifestos outlining their visions and promises for the future of India. While the Congress party presented its manifesto titled 'Nyay Patra', the BJP unveiled its manifesto named 'Sankalp Patra'. Let's delve into a comparative analysis of the promises made by each party in their manifestos. Economic Policies and Welfare Programs:

Hindustan Copper, Aster DM Healthcare, Kolte Patil Developers, Ramco Systems were among the top smallcap gainers. Abans Holdings, Transformers & Rectifiers, Waree Renewable Tech, IIFL Finance, KEI Industries, Anand Rathi Wealth, Llyods Metals, Force Motors, Suryoday Small Finance Bank, Motilal Oswal Financial Services among other smallcap stocks logged a double-digit growth in their share prices last week. Domestic equity benchmarks traded mixed and finally settled almost flat, taking a pause after three weeks of advance.

“If we analyse the healthcare space, it is looking very promising. Metropolis, Lal PathLabs, are looking very positive. The kind of breakout which we are observing on the daily as well as on the weekly time frame is bullish. So, I think these two stocks can do well. One can look to buy these stocks as overall structure for near-term to short-term is looking promising,” says Rajesh Palviya of Axis Securities. Edited excerpts:

Bandhan AMC, while discussing the new offering, said, “Innovation has consistently driven companies forward, and today, India's flourishing innovation landscape presents an exciting investment opportunity. We are observing ground-breaking transformations not only in technology but also in sectors like finance, auto, technology, healthcare, entertainment, retail, etc.

Neuberg Diagnostics is looking to raise $100 million by September, ahead of a planned public listing in two years, chairman GSK Velu said Friday. Neuberg, which runs a pan-India diagnostic chain, has appointed O3 Capital as the investment banker and is currently in talks with potential investors, Velu said in an interview. The Chennai-based company plans to use the fresh capital to expand its radiology business through acquisitions, he said. «Within two years, we want to list the company; we are doing the fundraise for some more M&A ramp up,» said Velu, also a serial entrepreneur having invested in eye care chain Maxivision. He is also the owner of medical equipment manufacturer Trivitron Healthcare and one of the key investors in Kaveri Hospitals. «With the proposed fundraise, we hope that our revenue will double in the next couple of years,» he added.

₹118 per equity share after the conclusion of its meeting earlier today. The hospitality chain said in a regulatory filing to the stock exchanges that the dividend will be payable to those shareholders whose names stand on the register of members of the company as on April 23- the record date set for the dividend. The dividend will be paid within 30 days.

Metropolis Healthcare, one of the leading Indian diagnostics companies, spiked 7.54% in today's intraday session to hit a new 52-week high of ₹1,935 apiece after investors reacted positively to the company's Q4 business, which was released on April 10, post-market hours. The company during the fourth quarter of last fiscal year recorded around a 10% YoY increase in overall revenue, alongside 15% YoY growth in revenue for its core business, maintaining a consistent rise in sales volumes across various segments.

nimesulide, a commonly used painkiller, be watchful. Pharma standards body Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert over nimesulide, saying the pill can trigger rashes on the skin (fixed drug eruption). It asked consumers and healthcare professionals to closely monitor the use of the drug and report any adverse reaction to the National Coordination Centre-Pharmacovigilance Programme of India of the IPC. According to the IPC, the drug is used in inflammatory conditions including joint disorders like rheumatoid arthritis, post-traumatic and post-operative painful conditions and fever, as well as in acute pain in orthopaedic, ENT and dental conditions.

₹1 lakh in a mutual fund scheme at the time of its launch in August 1998 would have swelled to a whopping ₹1.53 crore in 25 years? Sounds incredible but true! The rationale behind this is far simpler than it sounds: compounding. This means that being invested for a long period of time accrues greater dividends than one can imagine. Since mutual fund schemes, by default, reinvest the earnings made in the initial years, the returns in the later years are naturally higher than those earned in the initial years.

₹441, a 7.5% drop from its 10 April closing price of ₹477.70. Systematix Institutional Equities, meanwhile, has a “hold" rating on Wipro with a target of ₹440 per share. The Bengaluru-headquartered company has seen an exodus of top talent, including chief financial officer (CFO) Jatin Dalal, who joined rival Cognizant, and Rajan Kohli, the digital business head, who joined as chief executive officer (CEO) of Citrus Tech last April.

Carlyle is in formal discussions with TPG Growth to sell at least 25-30% stake in VLCC Healthcare Ltd, within a year of acquiring the wellness, beauty products and services company, said people aware of the matter. VLCC’s nearly 78% surge in valuation in just 12 months is the key trigger for Carlyle to take some money off the table, the people said. Last January, Carlyle paid Rs 2,700 crore to buy a controlling 66% stake in the three-decade-old homegrown brand that gave the buyout fund an entry into a rapidly growing market for wellness products but one that is facing disruption from younger, nimbler, direct-to-consumer (D2C) brands.

Warburg Pincus has bought a majority stake in Chennai-based Appasamy Associates, India's largest maker of ophthalmic equipment and intraocular lenses (IOLs). Financial details of the transaction were not disclosed. Appasamy operates across the entire value chain of ophthalmic devices — diagnostic, surgical equipment, and IOLs, according to company statement. ET was the first to report last July that Warburg Pincus was in advanced stages of talks to acquire Appasamy, having signed an exclusivity agreement, and started due diligence of the company. Promoters of Appasamy were expecting a valuation of ₹3,000-₹3,200 crore, ET reported at the time. Warburg planned to buy a 60-70% stake in the company and the business would continue to be run by the current management, ET reported. Post the deal, Appasamy will continue to be led by recently appointed CEO, Senthil Kumar who will drive the business going forward with support of the promoter family and in partnership with Warburg Pincus, according to the statement. Appasamy is also the exclusive distributor for Canon medical equipment in India.

MUMBAI : Warburg Pincus has picked up a stake in Chennai-based Appasamy Associates Pvt. Ltd., a manufacturer of ophthalmic equipment and devices, in what is the US-based private equity firm's largest investment in the healthcare sector in India, a statement released by the two firms said. Though the firms did not disclose the financial details of the deal, people with knowledge of the matter said that Warburg has acquired around 65% stake in the company for nearly $300 million.

The report that was released recently reports 7-12% annual salary increases within current jobs. Manufacturing and operations roles are in demand, so are talents for data, generative AI and machine learning roles. Sustainability and compliance skills have become hot topics in hiring. Renewables, electric vehicles (EVs) and the auto sector are expected to be in focus. Global capability centres (GCCs) are seeing a talent increase, it says. Senior-level hiring and salary insights

What’s interesting to note is that about 50% of this money has chased three sectors during the year.

This is an AI-generated live blog and has not been edited by LiveMint staff. The NIFTY Metal at (1.17%), NIFTY Realty at (0.9%) & NIFTY PSE at (0.69%) are currently the top performing sectors among the Sectoral Indices. While NIFTY Pharma at (-0.2%), NIFTY Healthcare at (-0.2%), NIFTY PVT Bank at (-0.11%) are currently the low performing sectors The Nifty 50 opened at 22642.75 (0%) , 0 points higher than the previous closing.